Kairos Pharma, LTD.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$5.6M | -$2.3M | -$1.7M |
| Operating expenses | $5.6M | $2.3M | $1.7M |
| Cash from operations | -$3.4M | -$4.0M | $81,000 |
| Impairments | $0 | $0 | $0 |
| Total assets | $6.5M | $5.8M | $965,000 |
| Total liabilities | — | $992,000 | $3.0M |
Shares outstanding 21.4M · Free float 68.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.